The prognosis for relapsing or refractory neuroblastoma (NB) remains dismal, with a five-year disease-free survival of < 20%, and no effective salvage treatment has been identified so far. 131I-metaiodobenzylguanidine (131I-MIBG) has come to play an essential role in the imaging and therapy of NB over the past 30 years. The role of 131I-MIBG in the treatment of NB is continually expanding. 131I...

Radioiodine treatments of patients with well-differentiated thyroid carcinoma have generally been safe and beneficial. Safety can be ensured while efficacy is increased through practical methods of dosimetry that measure body retention of 131I. Prescriptions for therapeutic 131I can be decreased when the retention level is high and increased when the level is low. Assays of serum free T4 will a...

Residual tumor resulting in tumor recurrence after various anticancer therapies is an unmet challenge in current clinical oncology. This study aimed to investigate the hypothesis that radioiodinated hypericin (131I-Hyp) may inhibit residual tumor recurrence after microwave ablation (MWA) on rat orthotopic liver allograft sarcoma models.Thirty Sprague-Dawley (SD) rats with hepatic tumors were di...

The previous pharmacokinetic methods can be only limited to drug analysis in vitro, which provide less information on the distribution and metabolismof drugs, and limit the interpretation and assessment of pharmacokinetics, the determination of metabolic principles, and evaluation of treatment effect. The objective of the study was to investigate the pharmacokinetic characteristics of gene reco...

Monoclonal antibody therapy may provide new treatment options in the management of metastatic breast cancer by selectively targeting tumors and producing a therapeutic effect, by delivering radiation or other toxins directly to tumor cells, or by producing an intrinsic immune inflammatory response. The effect of 131I-labeled humanized anti-Lewis(y) monoclonal antibody 3S193 (hu3S193) was compar...

In article number 2000802 by Xinhui Su, Xiaolian Sun, and co-workers, a 131I labeled ZnPc(COOH)4 conjugated ZnGa2O4:Cr3+ nanoplatform (131I-ZGCs-ZnPcC4) is developed for in vivo radiotherapy (RT) radiation-induced photodynamic therapy (PDT). can not only activate ZGCs long-lasting luminescence which further continuously activates the photosensitizer PDT, but also directly kill cancerous cells. ...

The Treatment Paradigm (Figure 1) Methimazole (MMI) was started 3 to 6 months before 131I therapy to restore euthyroidism and was discontinued 5 days (T-5) before 131I was initiated. On the same day, lithium, 900 mg/day was started. Seven days after 131I was administered (day T0), lithium was withdrawn, comprising 12 days of lithium, and oral prednisone was started at 0.5 mg/kg daily to avoid 1...

Dedifferentiation of well-differentiated thyroid carcinoma is a well-known phenomenon that may lead to the disappearance of radioiodine uptake in tumors and the inability to treat patients with radioiodine. We report a patient in whom the 131I uptake progressively diminished to such low levels after a cumulative dose of 31.5 GBq that further 131I administration was considered nonbeneficial. The...

To the Editor: Earlier studies demonstrated unexpected decrease of radioiodine (131I) renal excretion in patients adherent to low-iodine diet before 131I treatment while receiving furosemide [1,2]. This effects seems specific for humans, since it was not confirmed in a study on mice treated with low-iodine diet [3]. Other researchers [4-7] observed increase of 131I uptake to thyroid tissue or t...